ArticleMolecular therapy. Nucleic acids2026
Directed evolution of novel AAV capsids for enhanced delivery to mouse and human Schwann cells.
Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effective delivery to target cell types remains a major obstacle for gene therapy. Recombinant adeno-associated viruses (AAVs) have proven to be effective delivery vectors for the treatment of several diseases yet still have to demonstrate efficient delivery to many cell types, including cells of the peripheral nervous system. Schwann cells-essential for myelination, nerve regeneration, and general nerve maintenance-are strategic gene therapy targets for treating peripheral neuropathies but present unique challenges for gene delivery due to their protective barriers and diffuse localization throughout the body. To address this issue, we engineered novel AAV variants with enhanced transduction efficiency toward Schwann cells. Using directed evolution, we identified two groups of capsids with significantly improved delivery to these cells in mice or human. In addition to higher transduction efficiencies, human-tropic capsids also demonstrated higher resistance to antibody neutralization compared to natural serotypes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.